Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Stock Competitors & Peer Comparison

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, VRTX has a market cap of 133.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while VRTX trades at $526.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas VRTX's P/E ratio is 27.65. In terms of profitability, JAZZ's ROE is +0.21%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, JAZZ is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check VRTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, REGN has a market cap of 81.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while REGN trades at $788.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas REGN's P/E ratio is 17.27. In terms of profitability, JAZZ's ROE is +0.21%, compared to REGN's ROE of +0.14%. Regarding short-term risk, JAZZ is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check REGN's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, MRNA has a market cap of 78.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while MRNA trades at $198.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas MRNA's P/E ratio is -24.40. In terms of profitability, JAZZ's ROE is +0.21%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, JAZZ is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check MRNA's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while VRNA trades at $106.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas VRNA's P/E ratio is -102.80. In terms of profitability, JAZZ's ROE is +0.21%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, JAZZ is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check VRNA's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ARGX has a market cap of 59.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ARGX trades at $959.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ARGX's P/E ratio is 34.60. In terms of profitability, JAZZ's ROE is +0.21%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, JAZZ is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ARGX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, RVMDW has a market cap of 44.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while RVMDW trades at $11.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas RVMDW's P/E ratio is -1.29. In terms of profitability, JAZZ's ROE is +0.21%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, JAZZ is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check RVMDW's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, RVMD has a market cap of 43.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while RVMD trades at $204.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas RVMD's P/E ratio is -23.24. In terms of profitability, JAZZ's ROE is +0.21%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, JAZZ is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check RVMD's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas SGEN's P/E ratio is -57.19. In terms of profitability, JAZZ's ROE is +0.21%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, JAZZ is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check SGEN's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ONC has a market cap of 38.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ONC trades at $360.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ONC's P/E ratio is 63.53. In terms of profitability, JAZZ's ROE is +0.21%, compared to ONC's ROE of +0.14%. Regarding short-term risk, JAZZ is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ONC's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ALNY has a market cap of 34.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ALNY trades at $255.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ALNY's P/E ratio is 46.12. In terms of profitability, JAZZ's ROE is +0.21%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, JAZZ is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ALNY's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ROIV has a market cap of 25.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ROIV trades at $35.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ROIV's P/E ratio is -34.06. In terms of profitability, JAZZ's ROE is +0.21%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, JAZZ is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ROIV's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, INSM has a market cap of 25.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while INSM trades at $117.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas INSM's P/E ratio is -28.67. In terms of profitability, JAZZ's ROE is +0.21%, compared to INSM's ROE of -1.11%. Regarding short-term risk, JAZZ is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check INSM's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, INCY has a market cap of 25.1B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while INCY trades at $123.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas INCY's P/E ratio is 16.65. In terms of profitability, JAZZ's ROE is +0.21%, compared to INCY's ROE of +0.30%. Regarding short-term risk, JAZZ is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check INCY's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, BNTX has a market cap of 24.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while BNTX trades at $98.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas BNTX's P/E ratio is -12.78. In terms of profitability, JAZZ's ROE is +0.21%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, JAZZ is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BNTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, GMAB has a market cap of 21.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while GMAB trades at $35.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas GMAB's P/E ratio is 26.62. In terms of profitability, JAZZ's ROE is +0.21%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, JAZZ is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check GMAB's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas BGNE's P/E ratio is -22.55. In terms of profitability, JAZZ's ROE is +0.21%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, JAZZ is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BGNE's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, UTHR has a market cap of 20.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while UTHR trades at $475.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas UTHR's P/E ratio is 17.01. In terms of profitability, JAZZ's ROE is +0.21%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, JAZZ is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check UTHR's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, JAZZ's ROE is +0.21%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, JAZZ is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check DNA-WT's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, EXEL has a market cap of 14.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while EXEL trades at $58.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas EXEL's P/E ratio is 16.62. In terms of profitability, JAZZ's ROE is +0.21%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, JAZZ is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check EXEL's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ASND has a market cap of 14B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ASND trades at $225.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ASND's P/E ratio is -93.22. In terms of profitability, JAZZ's ROE is +0.21%, compared to ASND's ROE of +1.90%. Regarding short-term risk, JAZZ is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ASND's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, NBIX has a market cap of 13.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while NBIX trades at $138.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas NBIX's P/E ratio is 19.96. In terms of profitability, JAZZ's ROE is +0.21%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, JAZZ is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check NBIX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, HALO has a market cap of 13.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while HALO trades at $113.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas HALO's P/E ratio is 21.25. In terms of profitability, JAZZ's ROE is +0.21%, compared to HALO's ROE of +1.81%. Regarding short-term risk, JAZZ is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check HALO's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, BBIO has a market cap of 12.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while BBIO trades at $65.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas BBIO's P/E ratio is -17.53. In terms of profitability, JAZZ's ROE is +0.21%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, JAZZ is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BBIO's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas KRTX's P/E ratio is -28.09. In terms of profitability, JAZZ's ROE is +0.21%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, JAZZ is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check KRTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, SMMT has a market cap of 12.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while SMMT trades at $15.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas SMMT's P/E ratio is -13.94. In terms of profitability, JAZZ's ROE is +0.21%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, JAZZ is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check SMMT's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, MDGL has a market cap of 11.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while MDGL trades at $516.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas MDGL's P/E ratio is -40.36. In terms of profitability, JAZZ's ROE is +0.21%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, JAZZ is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check MDGL's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while BMRN trades at $60.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas BMRN's P/E ratio is 28.97. In terms of profitability, JAZZ's ROE is +0.21%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, JAZZ is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BMRN's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, TWST has a market cap of 11.4B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while TWST trades at $182.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas TWST's P/E ratio is -82.44. In terms of profitability, JAZZ's ROE is +0.21%, compared to TWST's ROE of -0.30%. Regarding short-term risk, JAZZ is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TWST's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while TECH trades at $72.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas TECH's P/E ratio is 37.43. In terms of profitability, JAZZ's ROE is +0.21%, compared to TECH's ROE of +0.09%. Regarding short-term risk, JAZZ is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check TECH's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while RNAM trades at $72.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas RNAM's P/E ratio is -17.39. In terms of profitability, JAZZ's ROE is +0.21%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, JAZZ is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check RNAM's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, TXG has a market cap of 10.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while TXG trades at $85.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas TXG's P/E ratio is -145.27. In terms of profitability, JAZZ's ROE is +0.21%, compared to TXG's ROE of -0.09%. Regarding short-term risk, JAZZ is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TXG's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, KRYS has a market cap of 10.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while KRYS trades at $345.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas KRYS's P/E ratio is 43.34. In terms of profitability, JAZZ's ROE is +0.21%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, JAZZ is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check KRYS's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, AXSM has a market cap of 10B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while AXSM trades at $195.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas AXSM's P/E ratio is -50.94. In terms of profitability, JAZZ's ROE is +0.21%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, JAZZ is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check AXSM's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas RXDX's P/E ratio is -56.47. In terms of profitability, JAZZ's ROE is +0.21%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, JAZZ is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check RXDX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ARWR has a market cap of 9.3B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ARWR trades at $65.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ARWR's P/E ratio is -29.30. In terms of profitability, JAZZ's ROE is +0.21%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, JAZZ is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ARWR's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, KYMR has a market cap of 9.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while KYMR trades at $111.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas KYMR's P/E ratio is -34.98. In terms of profitability, JAZZ's ROE is +0.21%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, JAZZ is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check KYMR's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while NUVL trades at $123.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas NUVL's P/E ratio is -21.79. In terms of profitability, JAZZ's ROE is +0.21%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, JAZZ is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check NUVL's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, PTGX has a market cap of 9.1B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while PTGX trades at $141.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas PTGX's P/E ratio is 137.73. In terms of profitability, JAZZ's ROE is +0.21%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, JAZZ is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PTGX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CAI has a market cap of 9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CAI trades at $31.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CAI's P/E ratio is 89.86. In terms of profitability, JAZZ's ROE is +0.21%, compared to CAI's ROE of +0.19%. Regarding short-term risk, JAZZ is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CAI's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CRNX trades at $84.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CRNX's P/E ratio is -16.86. In terms of profitability, JAZZ's ROE is +0.21%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, JAZZ is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CRNX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, IBRX has a market cap of 8.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while IBRX trades at $8.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas IBRX's P/E ratio is -8.70. In terms of profitability, JAZZ's ROE is +0.21%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, JAZZ is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check IBRX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while TGTX trades at $57.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas TGTX's P/E ratio is 20.81. In terms of profitability, JAZZ's ROE is +0.21%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, JAZZ is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TGTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas IMGN's P/E ratio is -111.55. In terms of profitability, JAZZ's ROE is +0.21%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, JAZZ is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check IMGN's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas BPMC's P/E ratio is -51.58. In terms of profitability, JAZZ's ROE is +0.21%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, JAZZ is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check BPMC's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while APGE trades at $135.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas APGE's P/E ratio is -31.19. In terms of profitability, JAZZ's ROE is +0.21%, compared to APGE's ROE of -0.30%. Regarding short-term risk, JAZZ is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check APGE's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CERE's P/E ratio is -16.47. In terms of profitability, JAZZ's ROE is +0.21%, compared to CERE's ROE of -0.72%. Regarding short-term risk, JAZZ is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CERE's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while PCVX trades at $56.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas PCVX's P/E ratio is -7.37. In terms of profitability, JAZZ's ROE is +0.21%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, JAZZ is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PCVX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CYTK has a market cap of 8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CYTK trades at $64.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CYTK's P/E ratio is -8.96. In terms of profitability, JAZZ's ROE is +0.21%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, JAZZ is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CYTK's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, PRAX has a market cap of 7.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while PRAX trades at $280.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas PRAX's P/E ratio is -21.72. In terms of profitability, JAZZ's ROE is +0.21%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, JAZZ is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PRAX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, SYRE has a market cap of 7.4B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while SYRE trades at $85.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas SYRE's P/E ratio is -43.94. In terms of profitability, JAZZ's ROE is +0.21%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, JAZZ is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check SYRE's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while MTSR trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas MTSR's P/E ratio is -23.58. In terms of profitability, JAZZ's ROE is +0.21%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, JAZZ is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check MTSR's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, IONS has a market cap of 7.4B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while IONS trades at $44.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas IONS's P/E ratio is -13.61. In terms of profitability, JAZZ's ROE is +0.21%, compared to IONS's ROE of -1.11%. Regarding short-term risk, JAZZ is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check IONS's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while IMVT trades at $33.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas IMVT's P/E ratio is -11.81. In terms of profitability, JAZZ's ROE is +0.21%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, JAZZ is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check IMVT's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while MRUS trades at $90.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas MRUS's P/E ratio is -17.05. In terms of profitability, JAZZ's ROE is +0.21%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, JAZZ is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check MRUS's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while RYTM trades at $98.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas RYTM's P/E ratio is -31.72. In terms of profitability, JAZZ's ROE is +0.21%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, JAZZ is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check RYTM's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ACLX trades at $115.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ACLX's P/E ratio is -28.27. In terms of profitability, JAZZ's ROE is +0.21%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, JAZZ is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ACLX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, BLTE has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while BLTE trades at $167.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas BLTE's P/E ratio is -89.48. In terms of profitability, JAZZ's ROE is +0.21%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, JAZZ is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check BLTE's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ABVX has a market cap of 6.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ABVX trades at $91.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ABVX's P/E ratio is -17.33. In terms of profitability, JAZZ's ROE is +0.21%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, JAZZ is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ABVX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas RETA's P/E ratio is -66.29. In terms of profitability, JAZZ's ROE is +0.21%, compared to RETA's ROE of +0.47%. Regarding short-term risk, JAZZ is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check RETA's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CNTA trades at $40.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CNTA's P/E ratio is -22.63. In terms of profitability, JAZZ's ROE is +0.21%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, JAZZ is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CNTA's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, LGND has a market cap of 6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while LGND trades at $301.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas LGND's P/E ratio is 33.10. In terms of profitability, JAZZ's ROE is +0.21%, compared to LGND's ROE of +0.20%. Regarding short-term risk, JAZZ is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check LGND's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CGON has a market cap of 5.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CGON trades at $67.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CGON's P/E ratio is -24.96. In terms of profitability, JAZZ's ROE is +0.21%, compared to CGON's ROE of -0.25%. Regarding short-term risk, JAZZ is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CGON's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while SRRK trades at $48.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas SRRK's P/E ratio is -14.10. In terms of profitability, JAZZ's ROE is +0.21%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, JAZZ is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check SRRK's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CDTX trades at $221.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CDTX's P/E ratio is -19.77. In terms of profitability, JAZZ's ROE is +0.21%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, JAZZ is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CDTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, TVTX has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while TVTX trades at $59.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas TVTX's P/E ratio is -132.09. In terms of profitability, JAZZ's ROE is +0.21%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, JAZZ is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TVTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, JAZZ's ROE is +0.21%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, JAZZ is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ABCM's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while COGT trades at $32.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas COGT's P/E ratio is -15.31. In terms of profitability, JAZZ's ROE is +0.21%, compared to COGT's ROE of -0.73%. Regarding short-term risk, JAZZ is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check COGT's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ISEE's P/E ratio is -22.44. In terms of profitability, JAZZ's ROE is +0.21%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, JAZZ is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ISEE's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, MIRM has a market cap of 5.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while MIRM trades at $89.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas MIRM's P/E ratio is -6.16. In terms of profitability, JAZZ's ROE is +0.21%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, JAZZ is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check MIRM's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while APLS trades at $41.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas APLS's P/E ratio is 38.35. In terms of profitability, JAZZ's ROE is +0.21%, compared to APLS's ROE of +0.40%. Regarding short-term risk, JAZZ is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check APLS's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, PTCT has a market cap of 5.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while PTCT trades at $62.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas PTCT's P/E ratio is -26.90. In terms of profitability, JAZZ's ROE is +0.21%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, JAZZ is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PTCT's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CRSP has a market cap of 5.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CRSP trades at $54.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CRSP's P/E ratio is -11.39. In terms of profitability, JAZZ's ROE is +0.21%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, JAZZ is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CRSP's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ORKA has a market cap of 5.1B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ORKA trades at $84.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ORKA's P/E ratio is -43.54. In terms of profitability, JAZZ's ROE is +0.21%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, JAZZ is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ORKA's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, DNTH has a market cap of 5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while DNTH trades at $88.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas DNTH's P/E ratio is -21.34. In terms of profitability, JAZZ's ROE is +0.21%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, JAZZ is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check DNTH's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ERAS has a market cap of 4.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ERAS trades at $14.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ERAS's P/E ratio is -15.32. In terms of profitability, JAZZ's ROE is +0.21%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, JAZZ is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ERAS's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, IOVA has a market cap of 4.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while IOVA trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas IOVA's P/E ratio is -15.07. In terms of profitability, JAZZ's ROE is +0.21%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, JAZZ is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check IOVA's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while MANE trades at $116.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas MANE's P/E ratio is -37.15. In terms of profitability, JAZZ's ROE is +0.21%, compared to MANE's ROE of -0.38%. Regarding short-term risk, JAZZ is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check MANE's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, DFTX has a market cap of 4.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while DFTX trades at $36.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas DFTX's P/E ratio is N/A. In terms of profitability, JAZZ's ROE is +0.21%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, JAZZ is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check DFTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while TERN trades at $52.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas TERN's P/E ratio is -51.41. In terms of profitability, JAZZ's ROE is +0.21%, compared to TERN's ROE of -0.20%. Regarding short-term risk, JAZZ is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check TERN's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ADPT trades at $29.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ADPT's P/E ratio is -71.78. In terms of profitability, JAZZ's ROE is +0.21%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, JAZZ is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ADPT's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while FOLD trades at $14.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas FOLD's P/E ratio is -161.00. In terms of profitability, JAZZ's ROE is +0.21%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, JAZZ is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check FOLD's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while AKRO trades at $54.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas AKRO's P/E ratio is -14.57. In terms of profitability, JAZZ's ROE is +0.21%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, JAZZ is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check AKRO's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ALPN's P/E ratio is -101.52. In terms of profitability, JAZZ's ROE is +0.21%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, JAZZ is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check ALPN's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas OPT's P/E ratio is -1.52. In terms of profitability, JAZZ's ROE is +0.21%, compared to OPT's ROE of +1.18%. Regarding short-term risk, JAZZ is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check OPT's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while EWTX trades at $39.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas EWTX's P/E ratio is -21.26. In terms of profitability, JAZZ's ROE is +0.21%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, JAZZ is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check EWTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while PRTC trades at $17.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas PRTC's P/E ratio is -3.78. In terms of profitability, JAZZ's ROE is +0.21%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, JAZZ is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PRTC's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, VKTX has a market cap of 4.1B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while VKTX trades at $35.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas VKTX's P/E ratio is -7.63. In terms of profitability, JAZZ's ROE is +0.21%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, JAZZ is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check VKTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas MRTX's P/E ratio is -4.82. In terms of profitability, JAZZ's ROE is +0.21%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, JAZZ is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check MRTX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, TNGX has a market cap of 4.1B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while TNGX trades at $24.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas TNGX's P/E ratio is -30.02. In terms of profitability, JAZZ's ROE is +0.21%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, JAZZ is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TNGX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, TLX has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while TLX trades at $11.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas TLX's P/E ratio is 119.52. In terms of profitability, JAZZ's ROE is +0.21%, compared to TLX's ROE of +0.07%. Regarding short-term risk, JAZZ is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check TLX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ABCL trades at $12.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ABCL's P/E ratio is -23.52. In terms of profitability, JAZZ's ROE is +0.21%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, JAZZ is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ABCL's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CELC has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CELC trades at $79.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CELC's P/E ratio is -18.49. In terms of profitability, JAZZ's ROE is +0.21%, compared to CELC's ROE of -3.51%. Regarding short-term risk, JAZZ is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check CELC's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CPRX trades at $31.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CPRX's P/E ratio is 17.49. In terms of profitability, JAZZ's ROE is +0.21%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, JAZZ is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CPRX's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, RLAY has a market cap of 3.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while RLAY trades at $17.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas RLAY's P/E ratio is -11.13. In terms of profitability, JAZZ's ROE is +0.21%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, JAZZ is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check RLAY's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas RYZB's P/E ratio is -57.86. In terms of profitability, JAZZ's ROE is +0.21%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, JAZZ is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check RYZB's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas CBAY's P/E ratio is -32.81. In terms of profitability, JAZZ's ROE is +0.21%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, JAZZ is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for JAZZ.Check CBAY's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, PBLS has a market cap of 3.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while PBLS trades at $31.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas PBLS's P/E ratio is -16.60. In terms of profitability, JAZZ's ROE is +0.21%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, JAZZ is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check PBLS's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, XENE has a market cap of 3.6B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while XENE trades at $36.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas XENE's P/E ratio is -7.86. In terms of profitability, JAZZ's ROE is +0.21%, compared to XENE's ROE of -0.44%. Regarding short-term risk, JAZZ is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check XENE's competition here

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, JAZZ stands at 14.9B. In comparison, ACAD has a market cap of 3.5B. Regarding current trading prices, JAZZ is priced at $237.95 on the NASDAQ, while ACAD trades at $20.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

JAZZ currently has a P/E ratio of 8.87, whereas ACAD's P/E ratio is 9.32. In terms of profitability, JAZZ's ROE is +0.21%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, JAZZ is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for JAZZ.Check ACAD's competition here